Highlights Bright Minds Biosciences Inc.

Stocks

DRUG

CA10919W4056

Biotechnology & Medical Research

Delayed Canadian Securities Exchange Other stock markets 18:33:01 18/06/2026 BST			5-day change	1st Jan Change
84.03 ^CAD	-0.81%		-2.06%	-23.91%

05-19	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
04-08	Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026.	CI

Highlights

05-19	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
02-13	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
01-09	Bright Minds Biosciences Closes its US$175 Million Public Offering	MT
01-08	Bright Minds Biosciences announces pricing of upsized US$175 million public offering of common stock at $90.00 per share	RE
01-06	Bright Minds Biosciences Launches US$100 Million Public Offering	MT
01-06	Bright Minds Biosciences Launches $100 Million Public Offering	MT
01-06	Bright Minds Biosciences Inc. Announces Positive Topline Results from Phase 2 Clinical Trial of BMB-101 in Patients with Absence Seizures and Developmental and Encephalopathic Epilepsies	CI
12-23	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
11-06	Bright Minds Biosciences Inc. Initiates New Prader-Willi Syndrome Program	CI
04/09/25	Bright Minds Biosciences Announces BMB-201 Outperforms Sumatriptan in Validated Preclinical Vascular Headache Model	CI
14/08/25	Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
16/05/25	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2025	CI
13/05/25	Bright Minds Biosciences Inc. Announces Positive Findings from Its Dba/2 Mouse Model Study Evaluating BMB-101	CI
13/02/25	Bright Minds Biosciences Inc. Reports Earnings Results for the First Quarter Ended December 31, 2024	CI
05/02/25	Bright Minds Biosciences Files For Offering Of Up To 1.6 Million Common Shares By The Selling Securityholders	RE
23/01/25	Piper Sandler Initiates Bright Minds Biosciences at Overweight	MT
10/01/25	Cantor Fitzgerald Initiates Bright Minds Biosciences With Overweight Rating	MT
10/01/25	HC Wainwright Initiates Bright Minds Biosciences With Buy Rating, $85 Price Target	MT
31/12/24	Bright Minds Biosciences Inc. Reports Earnings Results for the Full Year Ended September 30, 2024	CI
26/11/24	Baird Initiates Bright Minds Biosciences at Outperform	MT
16/10/24	Bright Minds Biosciences Says BMB-201 Had Similar Efficacy to Morphine in Preclinical Pain Models	MT
16/10/24	Bright Minds Biosciences Inc. Announces Positive Data from the Preclinical Testing of BMB-201	CI
12/09/24	Bright Minds Biosciences Inc. Initiates the Breakthrough Study	CI
14/08/24	Bright Minds Biosciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2024	CI
16/05/24	Bright Minds Biosciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI